Pfizer's Record-Breaking $2.3 Bil. Settlement With U.S. Attorney Imposes New Restrictions on Corporate Behavior
Executive Summary
Pfizer's $2.3 billion settlement with the U.S. Department of Justice is unprecedented in size and scope, resolving allegations of off-label marketing of four drugs and kickbacks to health care providers involving nine other drugs. Moreover, the deal includes the largest criminal fine ever imposed by the U.S. government in any matter
You may also be interested in...
Pfizer Agrees To Oversight Of Charitable Assistance Programs In DOJ Settlement
Second pharma charity kickback settlement in six months resolves claims Pfizer used charity to pay Medicare patient copays for three drugs.
Wyeth Rapamune Off-Label Marketing Settlement Will Not Alter Pfizer’s CIA
Pfizer subsidiary to pay $490.9 million to resolve criminal and civil liability for marketing its immunosuppressive for unapproved uses; actions predate Pfizer’s 2009 corporate integrity agreement.
Health Care Fraud Tipsters May Get Bigger Reward; Novartis Kickback Complaint Prompts CIA Review
HHS proposes to increase the potential reward for information leading to recovery of Medicare funds from $1,000 to $9.9 million; OIG is reviewing Novartis corporate integrity agreement compliance after government alleges company paid Myfortic kickbacks to pharmacies.